Skip to main content
SpringerLink
Log in

Injectable Pro-drugs Approach for Retina and Posterior Segment Disease

  • Chapter
  • First Online:
Drug Delivery for the Retina and Posterior Segment Disease

Abstract

Drug delivery to the posterior segment of the eye is an area of intense research and massive prospective. Because of the anatomical and protecting structure of the eye, drug delivery to the interior parts of the eye still remains bothersome. Regardless of the emergence of effectual drugs to treat various retinal diseases, doctors still wrestle with how best to administer these sight-saving drugs. An ideal route of administration would deliver therapeutic levels of drug to targeted parts in a remarkably protected way at the same time as providing negligible interruption to the patient’s quality of life. Promising innovative ocular drug delivery such as an injectable pro-drug strategy has been, and is being, employed for this purpose. This novel pro-drug approach offers manifold benefits over the parent compound as they enhance the membrane permeability, site specificity, transporter targeting ability, and aqueous solubility. In this chapter, we have discussed a range of pro-drug strategies, for instance, functional group approach, polymer and lipid conjugation with the drug moiety to impart lipophilicity or hydrophilicity or else to target nutrient transporters by conjugation with transporter-specific moieties, which have been extensively functional for improving drug penetration into the ocular tissues, in addition to overall ocular bioavailability, with minimal disruption of the ocular diffusion barriers. We have also discussed an update on the use of injectable pro-drug concept in ocular drug delivery and highlighted continuing academic and industrial research and progress in terms of ocular pro-drug design as well as delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Adibi SA. Renal assimilation of oligopeptides: physiological mechanisms and metabolic importance. Am J Phys. 1997;272:E723–36.

    CAS  Google Scholar 

  2. Aldern KA, Ciesla SL, Winegarden KL, Hostetler KY. Increased antiviral activity of 1-O-hexadecyloxypropyl-[2-(14) C]cidofovir in MRC-5 human lung fibroblasts is explained by unique cellular uptake and metabolism. Mol Pharmacol. 2003;63:678–81.

    Article  CAS  PubMed  Google Scholar 

  3. Alexander J, Cargill R, Michelson SR, Schwam H. (Acyloxy)alkyl carbamates as novel bioreversible prodrugs for amines: increased permeation through biological membranes. J Med Chem. 1988;31:318–22.

    Article  CAS  PubMed  Google Scholar 

  4. Al-Ghananeem AM, Crooks PA. Phase I and phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules. 2007;12:373–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Anand BS, Dey S, Mitra AK. Current prodrug strategies via membrane transporters/receptors. Expert Opin Biol Ther. 2002;2:607–20.

    Article  CAS  PubMed  Google Scholar 

  6. Anand BS, Hill JM, Dey S, Maruyama K, Bhattacharjee PS, Myles ME, Nashed YE, Mitra AK. In vivo antiviral efficacy of a dipeptide acyclovir prodrug, valval-acyclovir, against HSV-1 epithelial and stromal keratitis in the rabbit eye model. Invest Ophthalmol Vis Sci. 2003;44:2529–34.

    Article  PubMed  Google Scholar 

  7. Anand BS, Katragadda S, Nashed YE, Mitra AK. Amino acid prodrugs of acyclovir as possible antiviral agents against ocular hsv-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium. Curr Eye Res. 2004;29:153–66.

    Article  CAS  PubMed  Google Scholar 

  8. Anand BS, Mitra AK. Mechanism of corneal permeation of l-valyl ester of acyclovir: targeting the oligopeptide transporter on the rabbit cornea. Pharm Res. 2002;19:1194–202.

    Article  CAS  PubMed  Google Scholar 

  9. Atluri H, Anand BS, Patel J, Mitra AK. Mechanism of a model dipeptide transport across blood-ocular barriers following systemic administration. Exp Eye Res. 2004;78:815–22.

    Article  CAS  PubMed  Google Scholar 

  10. Aukunuru JV, Sunkara G, Bandi N, Thoreson WB, Kompella UB. Expression of multidrug resistance-associated protein (MRP) in human retinal pigment epithelial cells and its interaction with BAPSG, a novel aldose reductase inhibitor. Pharm Res. 2001;18:565–72.

    Article  CAS  PubMed  Google Scholar 

  11. Balimane PV, Sinko PJ. Involvement of multiple transporters in oral absorption of nucleosides analogues. Adv Drug Deliv Rev. 1999;39:183–09.

    Article  CAS  PubMed  Google Scholar 

  12. Banker AS, Arevalo JF, Munguia D, Rahhal FM, Ishimoto B, Berry C, Clercq ED, Ochabski R, Taskintuna I, Freeman WR. Intraocular pressure and aqueous humor dynamics in patients with AIDS treated with intravitreal cidofovir (HPMPC) for cytomegalovirus retinitis. Am J Ophthalmol. 1997;124:168–80.

    Article  CAS  PubMed  Google Scholar 

  13. Barot M, Bagui M, Gokulgandhi MR, Mitra AK. Prodrug Strategies in Ocular Drug Delivery. Med Chem. 2012;8:753–68.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  14. Barot M, Gaudana R, Samantha S, Earla R, Mitra AK. Development and evaluation of Dexamethasone Prodrugs for the treatment of ocular ailments. Invest Ophthalmol Vis Sci. 2009;50:4998.

    Article  Google Scholar 

  15. Barza M. Factors affecting the intraocular penetration of antibiotics: the influence of route, inflammation, animal species and tissue pigmentation. Scand J Infect Dis. 1978;14:151–9.

    CAS  Google Scholar 

  16. Bidanset DJ, Beadle JR, Wan WB, Hostetler KY, Kern ER. Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis. 2004;190:499–03.

    Article  CAS  PubMed  Google Scholar 

  17. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7:E820–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Bodor N, Farag HH, Somogyi G, Wu WM, Barros MD, Prokai L. Ocular-specific delivery of timolol by sequential bioactivation of its oxime and methoxime analogs. J Ocul Pharmacol Ther. 1997;13:389–03.

    Article  CAS  PubMed  Google Scholar 

  19. Broer S, Wagner CA, Lang F. Function and structure of heterodimeric amino acid transporters. Am J Phys. 2001;281:C1077–93.

    Article  Google Scholar 

  20. Cheng L, Hostetler KY, Chaidhawangul S, Gardner MF, Beadle JR, Toyoguchi M, Bergeron-Lynn G, Freeman WR. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir. Invest Ophthalmol Vis Sci. 2002;43:515–21.

    PubMed  Google Scholar 

  21. Cheng L, Hostetler KY, Lee J, Koh HJ, Beadle JR, Besho K, Toyoguchi M, Aldem K, Bovet JM, Freeman WR. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrug of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci. 2004;45:4138–44.

    Article  PubMed  Google Scholar 

  22. Cheng L, Hostetler KY, Toyoguchi M, Beadle JR, Rodanant N, Gardner MF, Aldern KA, Bergeron-Lynn G, Freeman WR. Ganciclovir release rates in vitreous from different formulations of 1-O-hexadecylpropanediol- 3-phospho-ganciclovir. J Ocul Pharmacol Ther. 2003;19:161–9.

    Article  CAS  PubMed  Google Scholar 

  23. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70:43–77.

    Article  CAS  PubMed  Google Scholar 

  24. Constable PA, Lawrenson JG, Dolman DE, Arden GB, Abbott NJ. P-Glycoprotein expression in human retinal pigment epithelium cell lines. Exp Eye Res. 2006;83:24–30.

    Article  CAS  PubMed  Google Scholar 

  25. Cundy KC, Lynch G, Shaw JP, Hitchcock MJ, Lee WA. Distribution and metabolism of intravitreal cidofovir and cyclic HPMPC in rabbits. Curr Eye Res. 1996;15:569–76.

    Article  CAS  PubMed  Google Scholar 

  26. Dal Pozzo F, Andrei G, Lebeau I, Beadle JR, Hostetler KY, De Clercq E, Snoeck R. In vitro evaluation of the anti-orf virus activity of alkoxyalkyl esters of CDV, cCDV and (S)-HPMPA. Antivir Res. 2007;75:52–7.

    Article  CAS  PubMed  Google Scholar 

  27. Deves R, Boyd CA. Transporters for cationic amino acids in animal cells: discovery, structure, and function. Physiol Rev. 1998;78:487–45.

    Article  CAS  PubMed  Google Scholar 

  28. Dey S, Anand BS, Patel J, Mitra AK. Transporters/receptors in the anterior chamber: pathways to explore ocular drug delivery strategies. Expert Opin Biol Ther. 2003;3:23–44.

    Article  CAS  PubMed  Google Scholar 

  29. Dias C, Nashed Y, Atluri H, Mitra A. Ocular penetration of acyclovir and its peptide prodrugs valacyclovir and val-valacyclovir following systemic administration in rabbits: An evaluation using ocular microdialysis and LC-MS. Curr Eye Res. 2002;25:243–52.

    Article  PubMed  Google Scholar 

  30. Ding S. Recent development in ophthalmic drug delivery. Pharm Sci Tech Today. 1998;1:328–35.

    Article  CAS  Google Scholar 

  31. Dun Y, Mysona B, Itagaki S, Martin-Studdard A, Ganapathy V, Smith SB. Functional and molecular analysis of D-serine transport in retinal Muller cells. Exp Eye Res. 2007;84:191–9.

    Article  CAS  PubMed  Google Scholar 

  32. Duvvuri S, Gandhi MD, Mitra AK. Effect of P-glycoprotein on the ocular disposition of a model substrate, quinidine. Curr Eye Res. 2003;27:345–53.

    Article  PubMed  Google Scholar 

  33. Duvvuri S, Majumdar S, Mitra AK. Role of metabolism in ocular drug delivery. Curr Drug Metab. 2004;5:507–15.

    Article  CAS  PubMed  Google Scholar 

  34. Farag HH, Wu WM, Barros MD, Somogyi G, Prokai L, Bodor N. Ocular-specific chemical delivery systems of betaxolol for safe local treatment of glaucoma. Drug Des Discov. 1997;15:117–30.

    CAS  PubMed  Google Scholar 

  35. Faulkner R, Sharif NA, Orr S, Sall K, Dubiner H, Whitson JT, Moster M, Craven ER, Curtis M, Pailliotet C, Martens K, Dahlin D. Aqueous humor concentrations of bimatoprost free acid, bimatoprost and travoprost free acid in cataract surgical patients administered multiple topical ocular doses of LUMIGAN or TRAVATAN. J Ocul Pharmacal Ther. 2010;26:147–56.

    Article  CAS  Google Scholar 

  36. Fukano Y, Kawazu K. Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats. Drug Metab Dispos. 2009;37:1622–34.

    Article  CAS  PubMed  Google Scholar 

  37. Gandhi MD, Pal D, Mitra AK. Identification and functional characterization of a Na(+)- independent large neutral amino acid transporter (LAT2) on ARPE-19 cells. Int J Pharm. 2004;275:189–200.

    Article  CAS  PubMed  Google Scholar 

  38. Gaudana R, Jwala J, Boddu SH, Mitra AK. Recent perspectives in ocular drug delivery. Pharm Res. 2009;26:1197–216.

    Article  CAS  PubMed  Google Scholar 

  39. Gerhart DZ, Leino RL, Drewes LR. Distribution of monocarboxylate transporters MCT1 and MCT2 in rat retina. Neuroscience. 1999;92:367–75.

    Article  CAS  PubMed  Google Scholar 

  40. Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41:961–4.

    CAS  PubMed  Google Scholar 

  41. Geroski DH, Edelhauser HF. Transscleral drug delivery for posterior segment disease. Adv Drug Del Rev. 2001;52:37–48.

    Article  CAS  Google Scholar 

  42. Gogate US, Repta AJ, Alexander J. N-(Acyloxyalkoxycarbonyl) derivatives as potential prodrugs of amines. I. Kinetics and mechanism of degradation in aqueous solutions. Int J Pharm. 1987;40:235–48.

    Article  CAS  Google Scholar 

  43. Gunda S, Hariharan S, Mitra AK. Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganciclovir (GCV): in vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. J Ocul Pharmacol Ther. 2006;22:465–76.

    Article  CAS  PubMed  Google Scholar 

  44. Hariharan S; Thakkar NR, Mitra AK. Transporter-targeted Drug Delivery to the Retina. Retina Today. 2009;4:57–62.

    Google Scholar 

  45. Herrero-Vanrell R, Refojo MF. Biodegradable microspheres for vitreoretinal drug delivery. Adv Drug Del Rev. 2001;52:5–16.

    Article  CAS  Google Scholar 

  46. Jain-Vakkalagadda B, Dey S, Pal D, Mitra AK. Identification and functional characterization of a Na+−independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest Ophthalmol Vis Sci. 2003;44:2919–27.

    Article  PubMed  Google Scholar 

  47. Jain-Vakkalagadda B, Pal D, Gunda S, Nashed Y, Ganapathy V, Mitra AK. Identification of a Na+−dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea. Mol Pharm. 2004;1:338–46.

    Article  CAS  PubMed  Google Scholar 

  48. Janoria KG, Gunda S, Boddu SHS, Mitra AK. Novel approaches to retinal drug delivery. Expert Opin Drug Deliv. 2007;4:371–88.

    Article  CAS  PubMed  Google Scholar 

  49. Janoria KG, Mitra AK. Effect of lactide/glycolide ratio on the in vitro release of ganciclovir and its lipophilic prodrug (GCV-monobutyrate) from PLGA microspheres. Int J Pharm. 2007;338:133–41.

    Article  CAS  PubMed  Google Scholar 

  50. Järvinen T, Niemi R. Prodrug Approaches to Ophthalmic Drug Delivery. In: Stella V, Borchardt R, Hageman M, Oliyai R, Maag H, Tilley J, editors. , vol. V. New York: Springer; 2007. p. 125–55.

    Google Scholar 

  51. Juntunen J, Huuskonen J, Laine K, Niemi R, Taipale H, Nevalainen T, Pate DW, Jarvinen T. Anandamide prodrugs. 1. Water-soluble phosphate esters of arachidonylethanolamide and R-methanandamide. Eur J Pharm Sci. 2003;19:37–43.

    Article  CAS  PubMed  Google Scholar 

  52. Juntunen J, Jarvinen T, Niemi R. In-vitro corneal permeation of cannabinoids and their water-soluble phosphate ester prodrugs. J Pharm Pharmacol. 2005;57:1153–7.

    Article  CAS  PubMed  Google Scholar 

  53. Kansara V, Hao Y, Mitra AK. Dipeptide monoester ganciclovir prodrugs for transscleral drug delivery: targeting the oligopeptide transporter on rabbit retina. J Ocul Pharmacol Ther. 2007;23:321–34.

    Article  CAS  PubMed  Google Scholar 

  54. Kansara V, Luo S, Balasubrahmanyam B, Pal D, Mitra AK. Biotin uptake and cellular translocation in human derived retinoblastoma cell line (Y-79): a role of hSMVT system. Int J Pharm. 2006;312:43–52.

    Article  CAS  PubMed  Google Scholar 

  55. Karla PK, Earla R, Boddu SH, Johnston TP, Pal D, Mitra A. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells. Curr Eye Res. 2009b;34:1–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  56. Karla PK, Pal D, Quinn T, Mitra AK. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int J Pharm. 2007;336:12–21.

    Article  CAS  PubMed  Google Scholar 

  57. Karla PK, Quinn TL, Herndon BL, Thomas P, Pal D, Mitra A. Expression of multidrug resistance associated protein 5 (MRP5) on cornea and its role in drug efflux. J Ocul Pharmacol Ther. 2009a;25:121–32.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Katragadda S, Gunda S, Hariharan S, Mitra AK. Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections. Int J Pharm. 2008;359:15–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Katragadda S, Talluri RS, Pal D, Mitra AK. Identification and characterization of a Na+− dependent neutral amino acid transporter, ASCT1, in rabbit corneal epithelial cell culture and rabbit cornea. Curr Eye Res. 2005;30:989–1002.

    Article  CAS  PubMed  Google Scholar 

  60. Kawakami S, Yamamura K, Mukai T, Nishida K, Nakamura J, Sakaeda T, Nakashima M, Sasaki H. Sustained ocular delivery of tilisolol to rabbits after topical administration or intravitreal injection of lipophilic prodrug incorporated in liposomes. J Pharm Pharmacol. 2001;53:1157–61.

    Article  CAS  PubMed  Google Scholar 

  61. Kekuda R, Torres-Zamorano V, Fei YJ, Prasad PD, Li HW, Mader LD, Leibach FH, Ganapathy V. Molecular and functional characterization of intestinal Na+-dependent neutral amino acid transporter b0. Am J Phys. 1997;272:G1463–72.

    CAS  Google Scholar 

  62. Kennedy BG, Mangini NJ. P-glycoprotein expression in human retinal pigment epithelium. Mol Vis. 2002;8:422–30.

    CAS  PubMed  Google Scholar 

  63. Kim JS, Beadle JR, Freeman WR, Hostetler KY, Hartmann K, Valiaeva N, Kozak I, Conner L, Trahan J, Aldern KA, Cheng L. A novel cytarabine crystalline lipid prodrug: Hexadecyloxypropyl cytarabine 3′,5′-cyclic monophosphate for proliferative vitreoretinopathy. Mol Vis. 2012;18:1907–17.

    CAS  PubMed Central  PubMed  Google Scholar 

  64. Kwatra D, Vaishya R, Gaudana R, Jwala J. In: Rautio J, editor. Prodrugs and targeted delivery towards beller ADME properties, vol. 47. Germany: Wiley-VCH; 2011. p. 181–01.

    Chapter  Google Scholar 

  65. Lee VH. Membrane transporters. Eur J Pharm Sci. 2000;11:S41–50.

    Article  CAS  PubMed  Google Scholar 

  66. Li YH, Tanno M, Itoh T, Yamada H. Role of monocarboxylic acid transport system in the intestinal absorption of an orally active beta lactam prodrug: carindacillin as a model. Int J Pharm. 1999;191:151–9.

    Article  CAS  PubMed  Google Scholar 

  67. Li Z, Bitha P, Lang SA, Lin YI. Synthesis of (alkoxycarbonyloxy)methyl, (acyloxy)methyl and (oxodioxolenyl)methyl carhamates a bioreversible prodrug moieties for amines. Bioorg Med Chem Lett. 1997;7:2909–12.

    Article  CAS  Google Scholar 

  68. Liederer BM, Borchardt RT. Enzymes involved in the bioconversion of ester-based prodrugs. J Pharm Sci. 2006;95:1177–95.

    Article  CAS  PubMed  Google Scholar 

  69. Lim JI, Anderson CT, Hutchinson A, Buggage RR, Grossniklaus HE. The role of gravity in gentamicin-induced toxic effects in a rabbit model. Arch Ophthalmol. 1994;112:1363–7.

    Article  CAS  PubMed  Google Scholar 

  70. Lu Y, Low PS. Folate mediated delivery of macromolecular anticancer therapeutic agents. Adv Drug Deliv Rev. 2002;54:675–93.

    Article  CAS  PubMed  Google Scholar 

  71. Majumdar S, Hingorani T, Srirangam R, Gadepalli RS, Rimoldi JM, Repka MA. Transcorneal permeation of L- and D-aspartate ester prodrugs of acyclovir: delineation of passive diffusion versus transporter involvement. Pharm Res. 2009;26:1261–9.

    Article  CAS  PubMed  Google Scholar 

  72. Majumdar S, Kansara V, Mitra AK. Vitreal pharmacokinetics of dipeptide monoester prodrugs of ganciclovir. J Ocul Pharmacol Ther. 2006;22:231–41.

    Article  CAS  PubMed  Google Scholar 

  73. Majumdar S, Nashed YE, Patel K, Jain R, Itahashi M, Neumann DM, Hill JM, Mitra AK. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: in vitro and in vivo evaluations. J Ocul Pharmacol Ther. 2005;21:463–74.

    Article  CAS  PubMed  Google Scholar 

  74. Malik P, Kadam RS, Cheruvu NP, Kompella UB. Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib. Mol Pharm. 2012;9:605–14.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  75. Mandell AI, Stentz F, Kitabchi AE. Dipivalyl epinephrine: a new pro-drug in the treatment of glaucoma. Ophthalmology. 1978;85:268–75.

    Article  CAS  PubMed  Google Scholar 

  76. Manna F, Chimenti F, Bolasco A, Lena R, Filippelli A, Falciani M, Fontana M. Beta-adrenoreceptor blocking heterocyclic oximes and ethers. Farmaco. 1996;51:699–06.

    CAS  PubMed  Google Scholar 

  77. Mannermaa E, Vellonen KS, Urtti A. Drug transport in corneal epithelium and blood-retina barrier: emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev. 2006;58:1136–63.

    Article  CAS  PubMed  Google Scholar 

  78. McComb RB, Bowers GN, Jr Posen S. Alkaline Phosphatase. New York/London: Plenum Press; 1979.

    Book  Google Scholar 

  79. Mitra AK, Anand BS, Duvvuri S. Drug delivery to the eye. Advances in Organ Biology. 2006;10:307–51.

    Article  CAS  Google Scholar 

  80. Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3650–5.

    Article  PubMed  Google Scholar 

  81. Neises B, Angew WS. Simple method for the esterification of carboxylic acids bernhard neises and wolfgang steglich. Chem Int Ed. 1978;17:522.

    Article  Google Scholar 

  82. Nielsen CU, Andersen A, Brodin B, Frokjaer S, Taub ME, Steffansen B. Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hpept1 in human intestinal caco-2 cell line. J Control Release. 2001;76:129–38.

    Article  CAS  PubMed  Google Scholar 

  83. Nielsen CU V°b J, Andersen R, Brodin B, Steffansen B. Recent advances in therapeutic applications of human peptide transporters. Expert Opin Ther Patents. 2005;15:153–66.

    Article  CAS  Google Scholar 

  84. Ocheltree SM, Keep RF, Shen H, Yang D, Hughes BA, Smith DE. Preliminary investigation into the expression of proton-coupled oligopeptide transporters in neural retina and retinal pigment epithelium (RPE): lack of functional activity in RPE plasma membranes. Pharm Res. 2003;20:1364–72.

    Article  CAS  PubMed  Google Scholar 

  85. Ogura Y. Drug delivery to the posterior segments of the eye. Adv Drug Del Rev. 2001;52:1–3.

    Article  CAS  Google Scholar 

  86. Palacin M, Estevez R, Bertran J, Zorzano A. Molecular biology of mammalian plasma membrane amino acid transporters. Physiol Rev. 1998;78:969–1054.

    Article  CAS  PubMed  Google Scholar 

  87. Pfeiffer R, Rossier G, Spindler B, Meier C, KĂ¼hn L, Verrey F. Amino acid transport of y+l-type by heterodimers of 4f2hc/cd98 and members of the glycoprotein-associated amino acid transporter family. EMBO J. 1999;18:49–57.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  88. Rathore MS, Gupta VB. Drug delivery enhancement strategies through cornea: a review. Asian J Pharm. 2007;1:40–6.

    Google Scholar 

  89. Rautio J, Kumpulainen H, Heimbach T, R O, Oh D, Järvinen T, Savolainen J. Prodrugs: design and clinical applications. Nat Rev Drug Discov. 2008;7:255–70.

    Article  CAS  PubMed  Google Scholar 

  90. Reddy IK. Ocular therapeutics and drug delivery: a multidisciplinary approach. 1st ed: Technomic Publishing Co., Inc.. Lancaster, Pennsylvania, USA; 1995.

    Google Scholar 

  91. Shimazaki A, Kirihara T, Rao PV, Tajima H, Matsugi T, Epstein DL. Effects of the new ethacrynic acid oxime derivative SA12590 on intraocular pressure in cats and monkeys. Biol Pharm Bull. 2007;30:1445–9.

    Article  CAS  PubMed  Google Scholar 

  92. Simplicio AL, Clancy JM, Gilmer JF. Prodrugs for amines. Molecules. 2008;13:519–47.

    Article  PubMed  PubMed Central  Google Scholar 

  93. Talluri RS, Gaudana R, Hariharan S, Mitra AK. Pharmacokinetics of stereoisomeric dipeptide prodrugs of acyclovir following intravenous and oral administrations in rats: A study involving corneal uptake following oral dosing. Ophthalmol Eye Dis. 2009;1:21–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  94. Talluri RS, Hariharan S, Karla PK, Mitra AK, Patricia D, Reza D. Drug delivery to cornea and conjunctiva-esterase and protease directed prodrug design. In: Dartt DA, Bex P, Mcloon L, Niederkorn J, editors. Ocular Periphery and Disorders. San Deigo, California: Elsevier, Academic Press; 2011. p. 42–53.

    Google Scholar 

  95. Talluri RS, Samanta SK, Gaudana R, Mitra AK. Synthesis, metabolism and cellular permeability of enzymatically stable dipeptide prodrugs of acyclovir. Int J Pharm. 2008;361:118–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  96. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci. 2000;89:1371–88.

    Article  CAS  PubMed  Google Scholar 

  97. Taskar P, Tatke A, Majumdar S. Advances in the use of prodrugs for drug delivery to the eye. Expert Opin Drug Deliv. 2017;14:49–63.

    Article  CAS  PubMed  Google Scholar 

  98. Taskintuna I, Banker AS, Floresaguilar M, Bergeronlynn G, Aldern KA, Hostetler KY, Freeman WR. Evaluation of a novel lipid prodrug for intraocular drug delivery: effect of acyclovir diphosphate dimyristoylglycerol in a rabbit model with herpes simplex virus-1 retinitis. Retina. 1997;17:57–64.

    Article  CAS  PubMed  Google Scholar 

  99. Testa B, Mayer JM. Hydrolysis in Drug and Prodrug Metabolism. Weinheim: Wiley-VCH Verlag GmbH; 2003.

    Book  Google Scholar 

  100. Torrents D, Estevez R, Pineda M, FernĂ¡ndez E, Lloberas J, Shi YB, Zorzano A, PalacĂ­n M. Identification and characterization of a membrane protein (y+l amino acid transporter-1) that associates with 4f2hc to encode the amino acid transport activity y+l: a candidate gene for lysinuric protein intolerance. J Biol Chem. 1998;273:32437–45.

    Article  CAS  PubMed  Google Scholar 

  101. Vadlapudi AD, Vadlapatla RK, Earla R, Sirimulla S, Bailey JB, Pal D, Mitra AK. Novel biotinylated lipid prodrugs of acyclovir for the treatment of herpetic keratitis (HK): transporter recognition, tissue stability and antiviral activity. Pharm Res. 2013;30:2063–76.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  102. Vadlapudi AD, Vadlapatla RK, Kwatra D, Earla R, Samanta SK, Pal D, Mitra AK. Targeted lipid based drug conjugates: a novel strategy for drug delivery. Int J Pharm. 2012;434:315–24.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  103. Wang L, Damji KF, Chialant D, Hodge WG. Hypotony after intravenous cidofovir therapy for the treatment of cytomegalovirus retinitis. Can J Ophthalmol. 2002;37:419–22.

    Article  PubMed  Google Scholar 

  104. Wheeler G. Gabapentin. Pfizer. Curr Opin Investig Drugs. 2002;3:470–7.

    CAS  PubMed  Google Scholar 

  105. Yasukawa T, Kimura H, Tabata Y, Ogura Y. Biodegradable scleral plugs for vitreoretinal drug delivery. Adv Drug Del Rev. 2001;52:25–36.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nootan Pharmacy College, Faculty of Pharmacy, Sankalchand Patel University, Visnagar, Gujarat, India

    Anita Patel & Jayvadan K. Patel

  2. College of Pharmacy, University of South Florida, Tampa, FL, USA

    Yashwant V. Pathak

Authors
  1. Anita Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jayvadan K. Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yashwant V. Pathak
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Pharmacy, Sankalchand Patel University, Gujarat, India

    Jayvadan K. Patel

  2. College of Pharmacy, University of South Florida, Tampa, FL, USA

    Vijaykumar Sutariya

  3. School of Medicine, Faculty of Health, Deakin University, Victoria, Australia

    Jagat Rakesh Kanwar

  4. College of Pharmacy, University of South Florida, Tampa, FL, USA

    Yashwant V. Pathak

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Patel, A., Patel, J.K., Pathak, Y.V. (2018). Injectable Pro-drugs Approach for Retina and Posterior Segment Disease. In: Patel, J., Sutariya, V., Kanwar, J., Pathak, Y. (eds) Drug Delivery for the Retina and Posterior Segment Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-95807-1_19

Download citation

Publish with us

Policies and ethics

Search

Navigation